Kaneq Bioscience Overview

  • Founded
  • 2012
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private

Kaneq Bioscience General Information


Developer of early-stage compounds intended to treat metabolic diseases and cancer. The company's compounds develop a protein tyrosine phosphatase1B ("PTP-1B") inhibitor for treating type 2 diabetes mellitus and therapies for hypertension and diabetes, enabling pharmaceutical companies to get high-value molecules for validated targets and discover several marketed drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 2900 -1000 De La Gauchetière ouest
  • Montreal, Quebec H3B 4W5
  • Canada
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kaneq Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 01-Jan-2020 Completed Generating Revenue
2. Early Stage VC (Series A) 01-Jan-2014 Completed Generating Revenue
1. Early Stage VC 22-Jan-2013 Completed Generating Revenue
To view Kaneq Bioscience’s complete valuation and funding history, request access »

Kaneq Bioscience Executive Team (3)

Name Title Board Seat Contact Info
Daniel Bouthillier Ph.D Co-Founder & President
Brian Kennedy Ph.D Co-Founder & Vice President, Biology
You’re viewing 2 of 3 executive team members. Get the full list »

Kaneq Bioscience Board Members (2)

Name Representing Role Since
Luc Marengère Ph.D TVM Capital Life Science Board Member 000 0000
You’re viewing 1 of 2 board members. Get the full list »